Neurocrine Biosciences (NBIX) vs Phibro Animal Health (PAHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neurocrine Biosciences (NBIX) has outperformed Phibro Animal Health (PAHC) over the past year, gaining 1.6% versus a gain of 0.8%. Over five years, PAHC leads with a +71.6% price change compared with +35.1% for NBIX. Neurocrine Biosciences is the larger company by market cap ($14.36 billion vs $1.52 billion), about 9.5 times the size.
On valuation, Phibro Animal Health trades at a lower forward P/E (9.7x vs 11.9x for Neurocrine Biosciences). Phibro Animal Health pays a dividend yielding 1.28%, while Neurocrine Biosciences does not currently pay one. Neurocrine Biosciences converts more of its revenue into profit, with a net margin of 16.7% versus 6.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBIX | PAHC |
|---|---|---|
| Share price | $141.25 | $37.40 |
| Market cap | $14.36B | $1.52B |
| 1-day change | -1.55% | -0.85% |
| YTD return | -0.41% | +0.11% |
| 1-year return | +1.56% | +0.78% |
| 5-year return | +35.12% | +71.56% |
| P/E ratio (TTM) | 20.71 | 15.39 |
| Forward P/E | 11.89 | 9.73 |
| EPS (TTM) | $6.82 | $2.43 |
| Dividend yield | 0.00% | 1.28% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $2.86B | $1.52B |
| Revenue growth (YoY) | +21.45% | +17.12% |
| Net income (latest FY) | $478.60M | $99.72M |
| Gross margin | 98.18% | 33.76% |
| Operating margin | 21.64% | 12.81% |
| Net margin | 16.73% | 6.57% |
| 52-week high | $186.12 | $60.08 |
| 52-week low | $122.14 | $28.25 |
| Distance from 52-week high | -24.11% | -37.75% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +46.75% | +17.65% |
| Average volume | 1.30M | 236.19K |
| Shares outstanding | 101.65M | 21.11M |
| Employees | 2,500 | 2,605 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Neurocrine Biosciences is about 9.5 times larger than Phibro Animal Health by market value ($14.36B vs $1.52B).
- Neurocrine Biosciences trades at a higher earnings multiple (20.7x vs 15.4x trailing P/E).
- Phibro Animal Health offers a meaningfully higher dividend yield (1.28% vs 0.00%).
- Neurocrine Biosciences is more profitable, keeping 16.7 cents of every revenue dollar as net income versus 6.6 cents for Phibro Animal Health.
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
NBIX vs PAHC FAQ
Which is bigger, Neurocrine Biosciences or Phibro Animal Health?
Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $14.36B compared with $1.52B for Phibro Animal Health (PAHC).
Which stock has performed better over the past year, NBIX or PAHC?
NBIX returned +1.56% over the past 12 months, compared with +0.78% for PAHC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NBIX or PAHC?
PAHC has the lower trailing P/E at 15.4, versus 20.7 for NBIX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Neurocrine Biosciences or Phibro Animal Health?
Phibro Animal Health pays a dividend yielding 1.28%, while Neurocrine Biosciences does not currently pay a regular dividend.
Are Neurocrine Biosciences and Phibro Animal Health in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Neurocrine Biosciences and Biotechnology: Pharmaceutical Preparations for Phibro Animal Health.